Among men with nonmetastatic castration-resistant prostate cancer, those who were treated with darolutamide had a 59% decreased risk of metastasis compared with placebo recipients.
from Latest articles from Cancer Therapy Advisor Male Reproductive Cancers http://bit.ly/2S1ftPq
from Latest articles from Cancer Therapy Advisor Male Reproductive Cancers http://bit.ly/2S1ftPq